Assessing the Effect of Pomalidomide or Carfilzomib Treatment on Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Gupta, Shaloo [1 ]
Clancy, Zoe [2 ]
Copher, Ronda [2 ]
Rosenberg, Aaron Seth [3 ]
机构：
[1] Kantar, New York, NY USA
[2] Celgene Corp, Summit, NJ USA
[3] Univ Calif Davis, Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA 95817 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Multiple myeloma; Patient Reported Measures; Pomalidomide;
D O I：
10.1016/j.clml.2019.09.443
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-117
引用
收藏
页码：E268 / E269
页数：3
相关论文
共 50 条
  • [1] Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
    Francesco Sparano
    Michele Cavo
    Pasquale Niscola
    Tommaso Caravita
    Fabio Efficace
    Supportive Care in Cancer, 2018, 26 : 2075 - 2090
  • [2] Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
    Sparano, Francesco
    Cavo, Michele
    Niscola, Pasquale
    Caravita, Tommaso
    Efficace, Fabio
    SUPPORTIVE CARE IN CANCER, 2018, 26 (07) : 2075 - 2090
  • [3] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
    Dimopoulos, M. A.
    Sonneveld, P.
    Siegel, D.
    Palumbo, A.
    San-Miguel, J.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256
  • [4] Evaluating Patient-Reported Outcomes and Wearable Data Among Individuals with Relapsed/Refractory Multiple Myeloma
    Banerjee, Rahul
    Brassil, Kelly
    Grossfeld, Trenton
    Barr, Austin
    Cowan, Andrew J.
    BLOOD, 2023, 142
  • [5] Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Romanus, Dorothy
    DasMahapatra, Pronabesh
    Hoole, Michael
    Lowe, Maria
    Curran, Chris
    Campbell, Scott
    Bell, Jill A.
    ONCOLOGIST, 2019, 24 (11): : 1479 - 1487
  • [6] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [7] Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8
    Dimopoulos, Meletios
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Vorobyev, Vladimir
    Quach, Hang
    Spicka, Ivan
    Radocha, Jakub
    Robak, Pawel
    Kim, Kihyun
    Cavo, Michele
    Suzuki, Kazuhito
    Wilkes, Jodie
    Morris, Kristin
    Pompilus, Farrah
    Purser, Molly
    Philips-Jones, Amy
    Zhou, Xiaoou
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Manteca, Maria-Victoria Mateos
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S9 - S9
  • [8] Leveraging patient-reported outcomes to measure frailty in relapsed/ refractory multiple myeloma
    Murugappan, Meena N.
    King-Kallimanis, Bellinda L.
    Bhatnagar, Vishal
    Kanapuru, Bindu
    Chen, Ting-Yu
    Horodniceanu, Erica G.
    Singh, Harpreet
    Kluetz, Paul G.
    QUALITY OF LIFE RESEARCH, 2021, 30 (SUPPL 1) : S73 - S74
  • [9] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
    Guidetti, Anna
    Prada, Claudia Paba
    Laubach, Jacob P.
    Varga, Cindy
    Maglio, Michelle E.
    McKenney, Mary
    Doss, Deborah
    Schlossman, Robert L.
    Mitsiades, Constantine
    Hideshima, Teru
    Gorgun, Gullu T.
    Ghobrial, Irene M.
    Raje, Noopur
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108
  • [10] Patient-reported symptom burden in relapsed or refractory multiple myeloma
    Williams, Loretta A.
    Wang, Xin Shelley
    Shi, Qiuling
    Lin, Huei-Kai
    Garcia-Gonzalez, Araceli
    Davis, Catherine C.
    Cleeland, Charles S.
    Orlowski, Robert Z.
    Zyczynski, Teresa Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345